HAVCR2 and neoplasm: In view of the further progress in this therapeutic landscape, we investigated the feasibility of triple gene editing of checkpoint molecules (PD-1, LAG-3, and TIM-3) in T cells for adoptive T cell therapy (ATT), as a means to improve anti-tumor effects and simultaneously avoid immune-mediated adverse effects as caused by checkpoint blockade.